The estimated Net Worth of Jingrong Jean Cui is at least 81.6 百万$ dollars as of 9 June 2020. Jingrong Cui owns over 9,500 units of Turning Point Therapeutics Inc stock worth over 41,074,512$ and over the last 5 years Jingrong sold TPTX stock worth over 40,480,759$.
Jingrong has made over 22 trades of the Turning Point Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Jingrong sold 9,500 units of TPTX stock worth 625,195$ on 9 June 2020.
The largest trade Jingrong's ever made was selling 118,500 units of Turning Point Therapeutics Inc stock on 5 December 2019 worth over 6,134,745$. On average, Jingrong trades about 37,268 units every 15 days since 2019. As of 9 June 2020 Jingrong still owns at least 540,383 units of Turning Point Therapeutics Inc stock.
You can see the complete history of Jingrong Cui stock trades at the bottom of the page.
Jingrong's mailing address filed with the SEC is C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, STE. 200, SAN DIEGO, CA, 92121.
Over the last 6 years, insiders at Turning Point Therapeutics Inc have traded over 45,947,838$ worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth 60,168,920$ . The most active insiders traders include Plc Gsk、Patrick Machado、Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of 4,727,594$. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth 88,654$.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include: